Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07504120

The Effect of Remotely Delivered Pilates on Physical , and Psychological Outcomes in Individuals With Multiple Sclerosis

Objectives Objective 1: To determine the effects of a 16-week remotely delivered Pilates intervention on walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS.

Objective 2: To examine the impact of a 16-week remotely delivered Pilates intervention on depression & anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.

Aim Aim 1: To assess whether the 16-week remotely delivered Pilates intervention significantly improves walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS Aim 2: To investigate whether the 16-week remotely delivered Pilates intervention significantly improves depression & anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.

Hypothesis Hypothesis 1: The 16-week remotely delivered Pilates intervention will significantly improve walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS.

Hypothesis 2: Participants receiving the 16-week remotely delivered Pilates intervention will demonstrate significantly greater improvements in depression & anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

The current study will determine the feasibility and efficacy of a 16-week remotely delivered Pilates intervention for improving physical and psychological outcomes, and QOL, compared with a control condition, in individuals with MS. This represents a significant step forward in examining Pilates as an accessible, complementary therapy in MS.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or older
  • Self-reported diagnosis of multiple sclerosis by a neurologist
  • Relapse-free for the past 30 days before screening
  • Able to speak and read English as the primary language
  • Access to the internet and e-mail,
  • Ability to use Zoom, and willingness to complete testing sessions and questionnaires
  • Ambulatory without an assistive device (for example, cane)
  • Low to moderate disability, defined as a score of 0-4 on the Patient-Determined Disease Steps (PDDS)
  • Insufficiently active, defined as a score < 14 on the Godin Leisure-Time Exercise Questionnaire-Health Contribution Score (GLTEQ-HCS)
  • Adequate visual ability and literacy to read materials printed in 14-point font
  • Currently treated with a disease-modifying therapy

Exclusion criteria

  • Pregnant
  • Elevated risk for strenuous or maximal exercise, defined as more than one "Yes" response on the Physical Activity Readiness Questionnaire (PAR-Q) during screening

Treatment and study plan

Pilates

Behavioral

REMOTLY PILATES EXERCISE

Primary outcomes

  1. Change from baseline in walking endurance (Six-Minute Walk Test distance)

    Time frame: Baseline and 16 weeks (end of treatment)

    Distance walked during the Six-Minute Walk Test (6MWT) will be measured in meters. The outcome is the change from baseline to 16 weeks in 6MWT distance.

  2. Change from baseline in walking speed (Timed 25-Foot Walk)

    Time frame: Baseline and 16 weeks (end of treatment)

    Walking speed will be assessed using the Timed 25-Foot Walk (T25FW). The outcome is the change from baseline to 16 weeks in time to walk 25 feet, measured in seconds.

  3. Change from baseline in balance (Berg Balance Scale)

    Time frame: Baseline and 16 weeks (end of treatment)

    Balance will be assessed using the Berg Balance Scale (BBS), a 14-item performance-based measure of static and dynamic balance. Each item is scored from 0 to 4, and the outcome will be the change from baseline to 16 weeks in the BBS total score (range 0-56), with higher scores indicating better balance and lower risk of falls.

  4. Change from baseline in fatigue (Fatigue Severity Scale)

    Time frame: Baseline and 16 weeks (end of treatment)

    Fatigue will be measured using the Fatigue Severity Scale (FSS), a 9-item questionnaire assessing the impact of fatigue on daily functioning. Each item is rated from 1 to 7, and the outcome will be the change from baseline to 16 weeks in the FSS mean score (range 1-7), with higher scores indicating more severe fatigue.

  5. Change from baseline in pain (Short-form McGill Pain Questionnaire)

    Time frame: Baseline and 16 weeks (end of treatment)

    Pain will be measured using the Short-form McGill Pain Questionnaire (SF-MPQ). The outcome is the change from baseline to 16 weeks in SF-MPQ total score.

Secondary outcomes

  1. Change from baseline in cognitive processing speed (Symbol Digit Modalities Test)

    Time frame: Baseline and 16 weeks (end of treatment)

    Cognitive processing speed will be assessed using the Symbol Digit Modalities Test (SDMT). The outcome is the change from baseline to 16 weeks in SDMT total score, with higher scores indicating better processing speed. SDMT scores typically range from 0 to about 110 correct responses.

  2. Change from baseline in verbal learning and memory (California Verbal Learning Test-II)

    Time frame: Baseline and 16 weeks (end of treatment)

    Verbal learning and memory will be assessed using the California Verbal Learning Test-II (CVLT-II). The outcome is the change from baseline to 16 weeks in CVLT-II total recall score, with higher scores indicating better verbal learning and memory. CVLT-II total recall scores typically range from 0 to about 80.

  3. Change from baseline in visuospatial learning and memory (Brief Visuospatial Memory Test-Revised)

    Time frame: Baseline and 16 weeks (end of treatment)

    Visuospatial learning and memory will be assessed using the Brief Visuospatial Memory Test-Revised (BVMT-R). The outcome is the change from baseline to 16 weeks in BVMT-R total recall score, with higher scores indicating better visuospatial memory. BVMT-R total recall scores typically range from 0 to 36.

  4. Change from baseline in depression symptoms

    Time frame: Baseline and 16 weeks (end of treatment)

    Depression will be measured using a validated questionnaire (e.g., the Hospital Anxiety and Depression Scale-Depression subscale or a similar instrument). The outcome is the change from baseline to 16 weeks in depression total score, with higher scores indicating greater depressive symptoms. Typical depression scales have ranges such as 0-21 (HADS-D) ; enter the exact range that matches the scale you are using.

  5. Change from baseline in anxiety symptoms

    Time frame: Baseline and 16 weeks (end of treatment)

    Anxiety will be measured using a validated questionnaire (e.g., the Hospital Anxiety and Depression Scale-Anxiety subscale or a similar instrument). The outcome is the change from baseline to 16 weeks in anxiety total score, with higher scores indicating greater anxiety. Typical anxiety scales have ranges such as 0-21 (HADS-A) or 0-63 (BAI); enter the exact range that matches the scale you are using.

  6. Change from baseline in health-related quality of life

    Time frame: Baseline and 16 weeks (end of treatment)

    Health-related quality of life will be assessed using a validated questionnaire (e.g., the MSQoL-54 or a comparable instrument). The outcome is the change from baseline to 16 weeks in the quality-of-life total score or composite score. For instruments scored 0-100, higher scores typically indicate better quality of life; specify the exact scoring range and direction according to your chosen measure.

Sponsors and collaborators

Lead sponsor

University of Illinois at Chicago

Other

Registry information

Official study title

Does Remotely Delivered Pilates Influence Physical and Psychological Outcomes in Individuals With Multiple Sclerosis?

Acronym: MS

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Mar 31, 2026
Registry last updated
Mar 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.